A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
The primary objective of this study is to compare the effect of panitumumab versus cetuximab on overall survival (OS) for chemorefractory metastatic colorectal cancer (mCRC) among patients with wild-type Kirsten rat Sarcoma-2 virus (KRAS) tumors.
Inclusion Criteria:
Exclusion Criteria:
Chongqing, Sichuan 400038, China
Hyderabad, Andhra Pradesh 500 024, India
Hyderabad, Andhra Pradesh 500 034, India
Faenza RA, 48018, Italy
Meldola FC, 47014, Italy
Goyang-si, Gyeonggi-do, 410-769, South Korea
Putzu City, Chiayi 61363, Taiwan